A generic version of the weight-loss medication containing the active ingredient liraglutide is expected to become available in the coming weeks. While the substance has been accessible as a generic treatment for diabetes for several months, it has previously been unavailable for weight management purposes.
The development is being facilitated by the expiration of patent protection in the European Union for liraglutide, one of the first active ingredients utilized in weight-loss injections. According to reports, Zentiva is anticipated to be the first company to release a generic weight-loss product, branded as “Nevolat”. Several other manufacturers are currently navigating the regulatory approval process.
Zentiva has indicated that the price of Nevolat will be significantly lower than currently available weight-loss injections. Generic medications typically see price reductions of 50 to 70 percent. Currently, Novo Nordisk, the original developer, markets liraglutide for weight reduction in Germany under the brand name Saxenda, with a list price of approximately €291 for a pack of five pens, each containing three milliliters.
While liraglutide is considered one of the older active ingredients within its class and generally recognized as less potent than newer alternatives, Zentiva emphasizes its commitment to accessibility. Company executives highlight a growing need for affordable weight-loss solutions, recognizing that the therapy shouldn’t be restricted to those who can afford it.
The potential for further price reductions will depend on the response of Novo Nordisk and the actions of other generic manufacturers. It is common for original patent holders to adjust pricing downwards after patent expiry and competition among generic producers can often drive prices even lower.
